T1D Exercise Study – Participants Wanted!

Do you have type 1 diabetes? We are currently recruiting participants for an exercise intervention!!! The study will include group fitness classes at FITOLOGY and a series of tests before, during and after the intervention. The purpose of this study is to evaluate how exercise could improve blood sugar control of adults and adolescents with […]

JDRF FY2014 Annual Report Released

Thanks for making the 2013-2014 a great year for JDRF and the type one community in Central PA! Many exciting things have happened this year in T1D research, and the Central PA Chapter of JDRF raised $1.3 million to support this research. We couldn’t have done it without you! Check out the full Annual Report

Making the T1D Vaccine a Reality

Nanoparticle-based vaccine is designed to re-educate the immune system and halt the attack on the pancreas Over the last three years, Selecta Bioscience, a clinical stage biotechnology company, has been developing nanoparticles called Synthetic Vaccine Particle (SVP) as an immunotherapy for Type 1 diabetes (T1D) with support from JDRF and it was announced this week […]

JDRF-Funded Research Leads to Beta Cell Replacement Breakthrough

A new method for converting stem cells to beta cells could speed encapsulated cell replacement product development and research to cure type 1 diabetes Insulin therapy has long been the only method of treating type 1 diabetes (T1D), but a major breakthrough in producing replacement beta cells is bringing new hope that more effective, alternative […]

Unlocking Type 1 Diabetes Data

JDRF partners with Tidepool on data integration software for better type 1 diabetes management JDRF is partnering with the non-profit organization Tidepool to develop a new data integration tool for people with type 1 diabetes (T1D) who use insulin pumps, continuous glucose monitors, or blood glucose meters. The new tool at the center of the […]

A New Switch Hitter for Type 1 Diabetes Discovered

Pancreatic cells are more adaptable and possess a greater potential for self-healing than previously assumed For decades, the prevailing wisdom was that beta cells could not regenerate and that their loss in type 1 diabetes (T1D) was irreversible—the reason why people with T1D require insulin injections for life. JDRF-funded research is helping rewrite the textbook […]

Research Teamwork is Key to Curing Type 1 Diabetes

JDRF takes center stage at Capitol Hill briefing on accelerating biomedical research progress Richard A. Insel, M.D., JDRF’s Chief Scientific Officer, joined other research leaders at a Congressional briefing on, “How the Research-by-Consortia Model Will Lead to Faster Cures” held recently in Washington D.C. The briefing brought together biomedical leaders from foundations, industry, government, and […]

JDRF Partner ViaCyte to Immediately Initiate Type 1 Diabetes Clinical Trial

Updated Sept. 18, 2014 JDRF’s partner ViaCyte recently announced the U.S. Food and Drug Administration (FDA) is allowing them to move forward with a clinical trial of its innovative type 1 diabetes (T1D) encapsulated cell replacement therapy called VC-01™ product candidate. The company plans to immediately initiate the first ever clinical evaluation of a stem […]

Oxygen – A Key Ingredient of Life

JDRF partners with Beta-O2 Technologies to develop a novel implantable encapsulation device for type 1 diabetes The dream for everyone with type 1 diabetes (T1D) is to permanently restore their body’s lost ability to produce insulin. This defines a cure for T1D and remains a top priority for JDRF. As we work towards this longer-term […]

Rebalancing the Immune System

Novel therapy to increase beneficial immune cells shows promise in pilot type 1 diabetes clinical study Type 1 diabetes (T1D) is caused when a person’s immune system mistakenly destroys their insulin-producing beta cells. How and why this misguided attack begins remains a mystery, but JDRF research has helped shed light on the disease process, opening […]